ClinicalTrials.gg
Status unknownNCT04213105Updated Dec 30, 2019

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

A Phase 1 interventional study of QL1206 and Prolia® in Healthy People, sponsored by Qilu Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-30.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of QL1206 and Prolia® in healthy adults

Read the detailed description

This is a phase I,single center, randomized, double-blind and parallel group clinical trial . The primary objective is to assess the pharmacokinetic similarity of single and subcutaneous injections of QL1206 or Prolia® in healthy volunteers. The secondary objective are to assess the Clinical safety and immunogenicity similarity of single and subcutaneous injections of QL1206 or Prolia® in healthy volunteers. Meanwhile,observing the pharmacodynamic similarities of QL1206 or Prolia® preliminarily. Subjects would receive a single 60mg(1ml) of QL1206 or through subcutaneous injection.

02

Conditions studied

  • Healthy People
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the form and fully understand the test content, process and possible adverse reactions, and be able to complete the study according to the test plan requirements;
  • Aged ≥18 years or ≤50 years, male or female (including the boundary value);
  • Agree to take effective measures throughout the study period (including not limited to: hormonal drugs of pregnancy, physical contraception, surgery, abstinence, etc., until at least 6 months after the last study is administered;
  • Clinical laboratory examination, chest X-ray, abdominal B-ultrasound, , physical examination, vital signs and various examinations are normal or abnormal without clinical significance

Exclusion criteria

Exclusion Criteria:

  • Occurred or suffering from osteomyelitis or ONJ (mandibular necrosis) previously.
  • Serum calcium levels are outside the normal range of the laboratory, or the subject uses calcium supplements in the screening period.
  • The dental or jaw disease that is active, requiring oral surgery; or planned for invasive dental surgery during the study; or dental or oral surgery wounds have not healed;
  • Subject has viral hepatitis (including and ), AIDS antibodies, and Treponema pallidum antibodies;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    QL1206

    QL1206 injection (60mg) by subcutaneous injection once on the first day

    Drug: QL1206

  • Active comparator
    Prolia®

    Prolia® injection (120mg) by subcutaneous injection once on the first day

    Drug: Prolia®

Interventions

  • DrugQL1206

    subcutaneous injection of 60 mg (1ml) only once,on the first day.

  • subcutaneous injection of 60 mg (1ml)only once,on the first day

    Also known as: Denosumab Injection

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve (AUC0-t )

    Area under the plasma concentration-time curve (AUC0-t ) from 0 o'clock to the last measurable concentration acquisition time t.

    Time frame: 134 day

  2. maximum plasma concentration(Cmax)

    the maximum plasma concentration of QL1206/Prolia from 0 o'clock to the last measurable concentration acquisition time t.

    Time frame: 134 day

Secondary outcomes

  1. Adverse events(AE)

    The adverse medical events that occur after the clinical trial subjects receive the test drug do not necessarily have a causal relationship with the treatment.

    Time frame: 134 day

  2. serum CTX1

    CTX1 is a serum type I collagen C-terminal peptide to detect the bone metastasis. the secondary outcome measures the percent change in serum CTX1 throughout the study from baseline to 134 day

    Time frame: 134 day

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Jilin University
    Changchun, Jilin 130000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2019 (actual). Primary completion is estimated for Oct 2020, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2019
First posted
Dec 30, 2019
StartActual
Oct 31, 2019
Primary completionEst.
Oct 31, 2020
CompletionEst.
Oct 31, 2020
Last update
Dec 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04213105
Responsible party
Sponsor
First posted
Dec 30, 2019
Start date
Oct 31, 2019
Primary completion
Oct 31, 2020 (estimated)
Completion
Oct 31, 2020 (estimated)
Last update
Dec 30, 2019

Study contacts

shunjiang yu, CMO
Contact
shunjiang.yu@qilu-pharma.com
0531-83129659
yanhua DING, Professor
principal investigator · The First Affiliated Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QL1206

Start the discussion